Cervical secretions in pregnant women colonized rectally with group B streptococci have high levels of antibodies to serotype III polysaccharide capsular antigen and protein R

Scandinavian Journal of Immunology

Volumn 47, Issue 2, 1998, Pages 179-188

  Hordnes, K ^a   Tynning, T ^a   Kvam, A I ^b   Bevanger, L ^b   Brown, T A ^c   Jonsson, R ^a   Haneberg, B ^d  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF FLORIDA   (United States)

^d NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BACTERIAL ANTIGEN; HAPTOCORRIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; POLYSACCHARIDE;

ARTICLE; BACTERIAL COLONIZATION; CONTROLLED STUDY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; LATEX AGGLUTINATION TEST; PREGNANCY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RECTUM; SEROTYPE; STREPTOCOCCUS AGALACTIAE; UTERINE CERVIX;

ANTIBODIES, BACTERIAL; CARRIER STATE; CERVIX UTERI; FEMALE; HUMANS; POLYSACCHARIDES, BACTERIAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RECTAL DISEASES; SEROTYPING; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE;

EID: 0031911938     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1998.00283.x     Document Type: Article

References (56)

1. Baker CJ, Edwards MS. Group B streptococcal infections. In: Remington JS, Klein JO, eds. Infectious Diseases of the Fetus and the Newborn Infant. Philadelphia: WB Saunders, 1995:980-1054.
2. Madoff LC, Paoletti LC, Tai JY, Kasper DL. Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes. J Clin Invest 1994;94:286-92.
3. Baker CJ, Rench MA, Edwards MS, Carpenter RJ, Hays BM, Kasper DL. Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. N Eng J Med 1988;319:1180-5.
4. Kasper DL, Paoletti LC, Wessels MR et al. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest 1996;98:2308-14.
5. Boyer KM, Papierniak CK, Gadzala CA, Parvin JD, Gotoff SP. Transplacental passage of IgG antibody to group B streptococcus serotype Ia. J Pediatr 1984;104:618-20.
6. Morell A, Sidiropoulos D, Herrmann U et al. IgG subclasses and antibodies to group B streptococci, pneumococci, and tetanus toxoid in preterm neonates after intravenous infusion of immunoglobulin to the mothers. Pediatr Res 1986;20:933-6.
7. Hordnes K, Digranes A, Haugen IL et al. Systemic and mucosal antibody responses to group B streptococci following immunization of the colonic-rectal mucosa. J Reprod Immunol 1995;28:247-62.
8. Hordnes K, Tynning T, Kvam AI, Jonsson R, Haneberg B. Colonization in the rectum and uterine cervix with group B streptococci may induce specific antibody responses in cervical secretions of pregnant women. Infect Immun 1996;64:1643-52.
9. Flores AE, Ferrieri P. Molecular species of R-protein antigens produced by clinical isolates of group B streptococci. J Clin Microbiol 1989;27:1050-4.
10. Stålhammar Carlemalm M, Stenberg L, Lindahl G. Protein rib: a novel group B streptococcal cell surface protein that confers protective immunity and is expressed by most strains causing invasive infections. J Exp Med 1993;177:1593-603.
11. Kvam AI, Efstratiou A, Bevanger L et al. Distribution of serovariants of group B streptococci in isolates from England and Norway. J Med Microbiol 1995;42:246-50.
12. Larsson C, Stålhammar Carlemalm M, Lindahl G. Experimental vaccination against group B streptococcus, an encapsulated bacterium, with highly purified preparations of cell surface proteins Rib and α. Infect Immun 1996;64:3518-23.
13. Bevanger L, Maeland JA. Type classification of group B streptococci by the fluorescent antibody test. Acta Pathol Microbiol Scand B 1977;85:357-62.
14. Naess AI, Bevanger L, Iversen OJ, Maeland JA. Evaluation of monoclonal antibodies in serovar classification of group B streptococci (GBS). Brief report. APMIS 1991;99:1058-60.
15. Bevanger L, Kvam AI, Maeland JA. A Streptococcus agalactiae R protein analysed by polyclonal and monoclonal antibodies. APMIS 1995;103:731-6.
16. Wessels MR, Benedi WJ, Jennings HJ, Michon F, DiFabio JL, Kasper DL. Isolation and characterization of type IV group B Streptococcus capsular polysaccharide. Infect Immun 1989;57: 1089-94.
17. Bevanger L, Mæland JA. Complete and incomplete Ibc protein fraction in group B streptococci. Acta Pathol Microbiol Immunol Scand B 1979;87:51-4.
18. Gray B, Dillon H, Pritchard D. Interaction of group B streptococcal type-specific polysaccharides with wheat germ agglutinin and other lectins. J Immunol Methods 1984;72:269-77.
19. Schalen C, Nilsson HO, Zeeberg B. New EIA for GBS type-specific antibodies. Pathogenic streptococci: present and future. Proceedings of the XII Lancefield International Symposium on Streptococci and Streptococcal Disease, St Petersburg, September 6-10, 1993. St Petersburg: Lancer, 1994:357-8.
20. Holm SE, Håkansson S. A simple and sensitive enzyme immunoassay for determination of soluble type-specific polysaccharide from group B streptococci. J Immunol Methods 1988;106:89-94.
21. Klavinskis LS, Bergmeier LA, Gao L et al. Mucosal or targeted lymph node immunization of macaques with a particulate SIVp27 protein elicits virus-specific CTL in the genito-rectal mucosa and draining lymph nodes. J Immunol 1996;157:2521-7.
22. Crowley-Nowick PA, Bell MC, Edwards RP, Brockwell RC, Partridge EE, Mestecky J. Rectal immunization with influenza vaccine induces IgA antibodies in the genital tract. Immunol Cell Biol 1997;75:A10.
23. Haneberg B, Kendall D, Amerongen HM, Apter FM, Kraehenbuhl JP, Neutra MR. Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces. Infect Immun 1994;62:15-23.
24. Thapar MA, Parr EL, Bozzola JJ, Parr MB. Secretory immune responses in the mouse vagina after parenteral or intravaginal immunization with an immunostimulating complex (ISCOM). Vaccine 1991;9:129-33.
25. Parr EL, Parr MB. A comparison of antibody titres in mouse uterine fluid after immunization by several routes, and the effect of the uterus on antibody titres in vaginal fluid. J Reprod Fertil 1990;89:619-25.
26. McDermott MR, Brais LJ, Evelegh MJ. Mucosal and systemic antiviral antibodies in mice inoculated intravaginally with herpes simplex virus type 2. J Gen Virol 1990;71:1497-504.
27. Menge AC, Michalek SM, Russell MW, Mestecky J. Immune response of the female rat genital tract after oral and local immunization with keyhole limpet hemocyanin conjugated to the cholera toxin B subunit. Infect Immun 1993;61:2162-71.
28. Forrest BD. Indirect measurement of intestinal immune responses to an orally administered attenuated bacterial vaccine. Infect Immun 1992;60:2023-9.
29. Wassen L, Schön K, Holmgren J, Jertborn M, Lycke N. Local intravaginal vaccination of the female genital tract. Scand J Immunol 1996;44:408-14.
30. Kozlowski PA, Cu-Uvin S, Neutra MR, Flanigan TP. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun 1997;65:1387-94.
31. Macpherson A, Khoo UY, Forgacs I, Philpott Howard J, Bjarnason I. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 1996;38:365-75.
32. Brandtzaeg P, Haraldsen G, Rugtveit J. Immunopathology of human inflammatory bowel disease. Springer Semin Immunopathol 1997;18:555-89.
33. Weltzin R, Hsu SA, Mittler ES, Georgakopoulos K, Monath TP. Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice. Antimicrob Agents Chemother 1994;38:2785-91.
34. Kauppi-Korkeila M, van Alphen L, Madore D, Saarinen L, Kähty H. Mechanism of antibody-mediated reduction of nasopharyngeal colonization by Haemophilus influenzae type b studied in an infant rat model. J Infect Dis 1996;174:1337-40.
35. Apter FM, Michetti P, Winner LS, Mack JA, Mekalanos JJ, Neutra MR, Analysis of the roles of antilipopolysaccharide and anti-cholera toxin immunoglobulin A (IgA) antibodies in protection against Vibrio cholerae and cholera toxin by use of monoclonal IgA antibodies in vivo. Infect Immun 1993;61:5279-85.
36. Czinn SJ, Cai A, Nedrud JG. Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization. Vaccine 1993;11:637-42.
37. Michetti P, Mahan MJ, Slauch JM, Mekalanos JJ, Neutra MR. Monoclonal secretory immunoglobulin A protects mice against oral challenge with the invasive pathogen Salmonella typhimurium. Infect Immun 1992;60:1786-92.
38. Medaglini D, Rush C, Sestini P, Pozzi G. Vaginal colonization with recombinant non-pathogenic gram-positive bacteria. Immunol Cell Biol 1997;75:A58.
39. Gregory RL, Filler SJ. Protective secretory immunoglobulin A antibodies in humans following oral immunization with Streptococcus mutans. Infect Immun 1987;55:2409-15.
40. Gregory RL, Hobbs LC, Kindle JC, VanTo T, Malmstrom HS. Immunodominant antigens of Streptococcus mutans in dental caries-resistant subjects. Hum Antibodies Hybridomas 1990;1: 132-6.
41. Cole MF, Fitzsimmons SP, Sheridan MJ, Xu Y. Humoral immunity to commensal oral bacteria: quantitation, specificity and avidity of serum IgG and IgM antibodies reactive with Actinobacillus actinomycetemcomitans in children. Microbiol Immunol 1995;39:591-8.
42. Gotoff SP, Odell C, Papierniak CK, Klegerman ME, Boyer KM. Human IgG antibody to group b Streptococcus type III: comparison of protective levels in a murine model with levels in infected human neonates. J Infect Dis 1986;153:511-9.
43. Vogel LC, Boyer KM, Gadzala CA, Gotoff SP. Prevalence of type-specific group B streptococcal antibody in pregnant women. J Pediatr 1980;96:1047-51.
44. Gray BM, Dillon HC Jr, Pritchard DG, Feinstein RA, Oh K, Michalek SM. Type-specific antibodies against group B streptococci in human serum, saliva and vaginal secretions. Adv Exp Med Biol 1987;216B:995-1003.
45. Gray BM, Pritchard DG, Dillon HCJ. Seroepidemiological studies of group B Streptococcus type II. J Infect Dis 1985;151:1073-80.
46. Marxmiller JN, Gray BM, Anthony BF. IgA antibody to group specific polysaccharide in secretions of carriers and noncarriers of group B streptococci. Adv Exp Med Biol 1987;2166:989-94.
47. Sellin M, Håkansson S, Norgren M. Phase-shift of polysaccharide capsule expression in group B streptococci, type III. Microb Pathog 1995;18:401-15.
48. Paoletti LC, Ross RA, Johnson KD. Cell growth rate regulates expression of group B Streptococcus type III capsular polysaccharide. Infect Immun 1996;64:1220-6.
49. Michel JL, Madoff LC, Kling DE, Kasper DL, Ausubel FM. Cloned alpha and beta C-protein antigens of group B streptococci elicit protective immunity. Infect Immun 1991;59:2023-8.
50. Madoff LC, Michel JL, Gong EW, Kling DE, Kasper DL. Group B streptococci escape host immunity by deletion of tandem repeat elements of the alpha C protein. Proc Natl Acad Sci USA 1996;93:4131-6.
51. Brady LJ, Boyle MD. Identification of non-immunoglobulin A-Fc-binding forms and low-molecular-weight secreted forms of the group B streptococcal beta antigen. Infect Immun 1989;57:1573-81.
52. Hordnes K, Tynning T, Brown TA, Haneberg B, Jonsson R. Nasal immunization with group B streptococci can induce high levels of specific IgA antibodies in cervicovaginal secretions of mice. Vaccine 1997;15:1244-51.
53. Pal S, Peterson EM, de la Maza LM. Intranasal immunization induces long-term protection in mice against a Chlamydia trachomatis genital challenge. Infect Immun 1996;64:5341-8.
54. Haneberg B, Aase A, Andersen SR et al. Humoral and cellular immune responses in humans to a nasal outer membrane vesicle vaccine against group B meningococci. Imniunol Cell Biol 1997;75:A76.
55. Brandtzaeg P, Haneberg B. Role of nasal-associated lymphoid tissue in the human mucosal immune system. Mucosal Immunology Update 1997;5:4-8.
56. Bergquist C, Johansson EL, Lagergård T, Holmgren J, Rudin A. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect Immun 1997;65:2676-84.